01143 CN ENGY STORAGEWatchlist
About CN ENGY STORAGE Company
TransAsia International Medical Technology Group Co., Ltd. (SwanAsia International Medical Technology for short) is a value-added service provider and electronics manufacturer focusing on the “Belt and Road” cross-border supply chain. It is headquartered in Hong Kong, China, and listed on the main board of the Hong Kong Stock Exchange in 2011 (stock code: 01143.HK). Based on the economic growth trend of countries along the Belt and Road, TransAsia International Medical Technology integrates upstream and downstream resources around value-added services in the supply chain of characteristic industries, selects key countries and cities with high economic growth and market development along the Belt and Road for strategic layout, adhering to the business philosophy of “technology-driven development” and aggregates cross-border brand enterprises. Its business involves various fields such as real estate supply chains, electronic product supply chains, and commodity supply chains based on AI big data technology and blockchain technology to reshape the value chain. At present, TransAsia International Medical Technology has deeply deployed important growth regions in Southeast Asia such as Thailand, the Philippines, Hong Kong, Singapore, and Vietnam, and has set up more than ten provincial branches in mainland China. On the basis of having a high-quality customer base and well-known brand businesses from around the world, we are committed to building a “new circulation” ecosystem along the Belt and Road Initiative to lead the healthy and sustainable development of the industry.
Tianfeng Securities: The recovery trend of consumer electronics is gradually showing that electronic fabrics are expected to reach an upward inflection point
Currently, the price and profit of electronic yarn/electronic cloth are at the bottom of history. This round of consumer electronics recovery is compounded by the rigidity of the supply side, and the industry is expected to usher in a new upward cycle.
Selected Gelonghui Announcements (Hong Kong Stocks) | Cinda Biotech's total product revenue in the third quarter exceeded 1.6 billion yuan and achieved a strong increase of more than 45% year-on-year
[Today's focus] Cinda Biotech (01801.HK)'s total product revenue for the third quarter exceeded 1.6 billion yuan and achieved a strong increase of more than 45% year on year. Cinda Biotech (01801.HK) announced that in the third quarter of 2023, the company achieved total product revenue exceeding RMB 1.6 billion, a strong increase of more than 45% over the previous year, and maintained significant growth over the previous month, and continued to improve marketing output and efficiency. In the third quarter of 2023, under the clear market demand for high-quality, innovative drugs with high clinical value, the company leveraged a diversified product portfolio, a wide range of indications and medical insurance coverage, and comprehensive access channels,
China Energy Storage to Cooperate on Energy-Related Projects With CSG Smart Science Unit
China Energy Storage Technology Development (HKG:1143), formerly Link-Asia International MedTech Group, has entered into a cooperation agreement with CSG (Shanghai) New Energy Development. The two par